Loading...
•
Sep 30, 2022
Harrow Q3 2022 Earnings Report
Announced third quarter 2022 financial results, highlighting FDA approval for IHEEZO and the launch of Fortisite and atropine.com.
Key Takeaways
Harrow announced its Q3 2022 results, marking an inflection point with FDA approval for IHEEZO, launch of Fortisite, and the sale of its non-ophthalmology compounded product line, focusing the company entirely on the U.S. ophthalmic pharmaceutical market.
Received FDA approval for IHEEZO for ocular surface anesthesia.
Launched Fortisite, a new suite of compounded products.
Sold non-ophthalmology compounded product line to focus on the U.S. ophthalmic pharmaceutical market.
Launched atropine.com to market compounded atropine formulations.
Forward Guidance
No specific forward guidance was provided in the press release.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...